$7.050
+0.470 (+6.66%)At close
RXST News
RXST Events
RxSight Withdraws 2026 Guidance
In connection with the leadership transition, RxSight announced Wednesday that it withdrew 2026 guidance and will resume formal guidance in early 2027.
RxSight Reports Q2 Revenue of $33.74M, Exceeding Expectations
Reports Q2 revenue $33.74M, consensus $32.55M. "It is a privilege to join RxSight and to work alongside the talented team that pioneered an entirely new category in cataract surgery with the only commercially available IOL platform that enables physicians to adjust and personalize vision after surgery," said Aziz Mottiwala, President and Chief Executive Officer of RxSight. "The opportunity ahead is significant, and our immediate priority is to strengthen commercial execution, deepen adoption across our installed base and translate the value of adjustability into durable growth. To support those priorities, I have commenced a comprehensive review of the business. While underlying trends remain generally consistent with our prior expectations, withdrawing 2026 guidance gives us the flexibility to establish the right operating plan and focus our resources on the core business, our pipeline and the Alcon collaboration."
RxSight Appoints Aziz Mottiwala as New CEO
RxSight (RXST) announced a planned leadership transition effective July 20, with Aziz Mottiwala appointed president and CEO, succeeding Ron Kurtz, who will continue to serve as chief medical officer. Mottiwala most recently served as chief commercial officer at Tarsus Pharmaceuticals (TARS). In connection with this transition, Kurtz will resign from the board of directors, at which time Mottiwala will be appointed to the board. The company is not updating its previously communicated financial guidance in connection with this announcement.
RxSight Adjusts FY26 Revenue Outlook to $129.24M
Consensus $129.24M. The company said that the FY26 revenue view is inclusive of RxSight sales and revenue recognized from the RxSight Alcon Strategic Collaboration, comprised of: Sales of $110M-$120M, below previous guidance of $120M-$135M; Collaboration Agreement revenue of $30M-$40M, subject to the terms and conditions described in the Current Report on Form 8-K filed with the Securities and Exchange Commission on or about the date hereof; Gross margin of 73% to 75%, above previous guidance of 70% to 72%; and Operating expense at the high-end of $150M-$160M, in line with previous guidance.
RxSight Expects Q2 2026 Revenue of $5M to $7M
Yesterday, the company said that the preliminary revenue view includes $5M-$7M in revenue recognized from the RxSight Alcon Strategic Collaboration, with the specific amount expected to be reported with the company's financial results for the second quarter of 2026 in August 2026. RxSight also expects sales of roughly $27M, including the sale of 24,917 Light Adjustable Lens units and 11 Light Delivery Devices units; 1 rental unit placed. "While we faced meaningful commercial headwinds in Q2, including from more widespread competitive trialing, the unique ability of RxSight's Light Adjustable Technology to customize visual outcomes continued to deliver significant clinical benefits to thousands of patients around the world," said Dr. Ron Kurtz, Chief Executive Officer and President of RxSight. "To position the company for deeper penetration of current, next-generation, and collaboration products, we are accelerating investments in our LAL sales force and commercial capabilities, while maintaining a disciplined approach to overall spending. By leveraging our differentiated technology, large customer base, strong balance sheet and exciting pipeline, we believe RxSight is well positioned to drive both high-margin implant sales and future royalty income, thereby empowering doctors to deliver the industry's premier outcomes for even more of their patients."
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.